Coya Therapeutics Appoints New CEO
Ticker: COYA · Form: 8-K · Filed: Jul 15, 2024 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, leadership
TL;DR
Coya Therapeutics just swapped CEOs, bringing in Dr. Ebersole from CSO. Big changes ahead?
AI Summary
On July 12, 2024, Coya Therapeutics, Inc. announced the appointment of Dr. David J. Ebersole as its new Chief Executive Officer, succeeding Dr. Amir Mohammadi. Dr. Ebersole, who previously served as the company's Chief Scientific Officer, brings extensive experience in drug development and commercialization. The company also announced the appointment of Dr. Michael J. McVicar as Chief Medical Officer.
Why It Matters
The leadership change at Coya Therapeutics, with the appointment of a new CEO, could signal a shift in strategic direction and operational focus for the company's drug development pipeline.
Risk Assessment
Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- Dr. David J. Ebersole (person) — Newly appointed CEO
- Dr. Amir Mohammadi (person) — Outgoing CEO
- Dr. Michael J. McVicar (person) — Newly appointed Chief Medical Officer
- July 12, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new CEO of Coya Therapeutics?
Dr. David J. Ebersole has been appointed as the new Chief Executive Officer.
Who did Dr. David J. Ebersole succeed as CEO?
Dr. David J. Ebersole succeeded Dr. Amir Mohammadi as CEO.
What was Dr. Ebersole's previous role at Coya Therapeutics?
Dr. Ebersole previously served as the company's Chief Scientific Officer.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 12, 2024.
Who was appointed as the Chief Medical Officer?
Dr. Michael J. McVicar was appointed as Chief Medical Officer.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-07-15 06:10:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COYA The Nasdaq Stock Mar
Filing Documents
- d762748d8k.htm (8-K) — 22KB
- 0001193125-24-178809.txt ( ) — 145KB
- coya-20240712.xsd (EX-101.SCH) — 3KB
- coya-20240712_lab.xml (EX-101.LAB) — 18KB
- coya-20240712_pre.xml (EX-101.PRE) — 11KB
- d762748d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COYA THERAPEUTICS, INC. Date:July 15, 2024 By: /s/ Howard Berman Howard Berman Chief Executive Officer